14-Sep-2017 - Affimed GmbH

Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer

Affimed N.V. announced  the appointment of Dr. Wolfgang Fischer as Chief Operating Officer.

"We are very pleased that Dr. Wolfgang Fischer has joined our management team as COO," said Dr. Adi Hoess, Chief Executive Officer of Affimed. "With his solid track record in drug development and project management as well as his strong immunology and oncology background, Wolfgang's expertise will support the Company as we continue to advance our unique immune cell engagers through clinical development."

Dr. Fischer brings to Affimed 20 years of experience in research and drug development with a focus on oncology, immunology and pharmacology. He joins the Company from Sandoz Biopharmaceuticals (Novartis Group), where he managed the development and registration of Sandoz' biosimilar pipeline assets since 2012 and served as Global Head of Program and Project Management since 2014. Prior to joining Sandoz, he held various positions of increasing responsibility within the Novartis Group since 2003, including Medical Director Oncology for Novartis Pharma Switzerland AG as well as Regional Medical Director Hematology (Emerging Growth Markets), where he was responsible for the Hematology Medical Affairs program and supported the launch of several products in various countries.

"Affimed's strong technology base and growing pipeline of tetravalent bispecific antibodies have made the Company a leader in immune cell engagement, particularly in NK cell-based immunotherapy," said Dr. Wolfgang Fischer. "I am excited to join Affimed's team, which has generated a number of uniquely positioned clinical and pre-clinical product candidates. I am fully committed to contributing to Affimed's success as we continue to address the existing medical need in hematologic and solid tumor indications."

Dr. Wolfgang Fischer holds a Ph.D. in Cancer Research from the Swiss Federal Institute of Technology (ETH), Zurich, Switzerland. Thereafter, he completed postdoctoral fellowships at the Swiss Institute of Experimental Cancer Research, Lausanne, Switzerland and at the Scripps Research Institute, Department of Immunology, La Jolla, CA, USA, followed by a state doctorate (Habilitation) in Pharmacology and Toxicology at the Medical School of the University of Wuerzburg in Germany in 2003.

Facts, background information, dossiers
  • personnel changes
More about Affimed
  • News

    Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer

    Affimed Therapeutics AG announced the appointment of Dr. Jens-Peter Marschner as Chief Medical Officer, effective October 1st, 2013. Dr. Marschner recently joined Affimed from Merck KGaA. He has 18 years of professional experience in clinical development with a focus on biological compounds ... more

    Amphivena Completes $14 Million Equity Financing and Signs Agreement with Janssen

    Affimed Therapeutics AG announced that its subsidiary Amphivena Therapeutics Inc., a drug discovery company developing bispecific TandAb antibodies to treat hematological tumors, has successfully completed a $14 million Series A equity financing. The Series A financing was led by MPM Capita ... more

    Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study

    Affimed Therapeutics AG announced that the first patients with Hodgkin's Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin's Lymphoma patients across two centers in Europe and ... more

  • Companies

    Affimed GmbH

    Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. more